CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment

Artjoms Spaks; Darja Svirina; Irina Spaka; Inta Jaunalksne; Donats Breiva; Ilmars Tracums; Dainis Krievins

doi:10.3109/1354750X.2016.1172111

CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment

Artjoms Spaks (Corresponding Author)
, Darja Svirina
, Irina Spaka
, Inta Jaunalksne
, Donats Breiva
, Ilmars Tracums
, Dainis Krievins

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

Objective: To evaluate the association of CXC chemokine ligand 4 (CXCL4) plasma levels with tumour angiogenesis in non-small cell lung cancer (NSCLC) and to assess association of CXCL4 with clinical outcomes. Patients and methods: Fifty patients with early stage NSCLC who underwent pulmonary resection. CXCL4 levels were analysed by ELISA. Angiogenesis was assessed by immunohistochemistry, and microvessel density (MVD) count. Results: There was positive correlation between MVD and CXCL4 levels. Patients with higher CXCL4 levels had worse overall and disease-free survival. Conclusions: Plasma levels of CXCL4 are associated with tumour vascularity. Increased CXCL4 levels in NSCLC patients undergoing treatment may indicate active cancer-induced angiogenesis associated with relapse and worse outcome.

Original language	English
Pages (from-to)	474-478
Number of pages	5
Journal	Biomarkers
Volume	21
Issue number	5
DOIs	https://doi.org/10.3109/1354750X.2016.1172111
Publication status	Published - 3 Jul 2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords*

Angiogenesis
chemokines
CXC chemokine ligand 4
non-small cell lung cancer
platelet factor 4

Field of Science*

1.6 Biological sciences
3.2 Clinical medicine
3.1 Basic medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.3109/1354750X.2016.1172111

Cite this

@article{4050f47bcb944e6885fc8cb912b6fe2f,

title = "CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment",

abstract = "Objective: To evaluate the association of CXC chemokine ligand 4 (CXCL4) plasma levels with tumour angiogenesis in non-small cell lung cancer (NSCLC) and to assess association of CXCL4 with clinical outcomes. Patients and methods: Fifty patients with early stage NSCLC who underwent pulmonary resection. CXCL4 levels were analysed by ELISA. Angiogenesis was assessed by immunohistochemistry, and microvessel density (MVD) count. Results: There was positive correlation between MVD and CXCL4 levels. Patients with higher CXCL4 levels had worse overall and disease-free survival. Conclusions: Plasma levels of CXCL4 are associated with tumour vascularity. Increased CXCL4 levels in NSCLC patients undergoing treatment may indicate active cancer-induced angiogenesis associated with relapse and worse outcome.",

keywords = "Angiogenesis, chemokines, CXC chemokine ligand 4, non-small cell lung cancer, platelet factor 4",

author = "Artjoms Spaks and Darja Svirina and Irina Spaka and Inta Jaunalksne and Donats Breiva and Ilmars Tracums and Dainis Krievins",

year = "2016",

month = jul,

day = "3",

doi = "10.3109/1354750X.2016.1172111",

language = "English",

volume = "21",

pages = "474--478",

journal = "Biomarkers",

issn = "1354-750X",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment. / Spaks, Artjoms (Corresponding Author); Svirina, Darja; Spaka, Irina et al.
In: Biomarkers, Vol. 21, No. 5, 03.07.2016, p. 474-478.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment

AU - Spaks, Artjoms

AU - Svirina, Darja

AU - Spaka, Irina

AU - Jaunalksne, Inta

AU - Breiva, Donats

AU - Tracums, Ilmars

AU - Krievins, Dainis

PY - 2016/7/3

Y1 - 2016/7/3

N2 - Objective: To evaluate the association of CXC chemokine ligand 4 (CXCL4) plasma levels with tumour angiogenesis in non-small cell lung cancer (NSCLC) and to assess association of CXCL4 with clinical outcomes. Patients and methods: Fifty patients with early stage NSCLC who underwent pulmonary resection. CXCL4 levels were analysed by ELISA. Angiogenesis was assessed by immunohistochemistry, and microvessel density (MVD) count. Results: There was positive correlation between MVD and CXCL4 levels. Patients with higher CXCL4 levels had worse overall and disease-free survival. Conclusions: Plasma levels of CXCL4 are associated with tumour vascularity. Increased CXCL4 levels in NSCLC patients undergoing treatment may indicate active cancer-induced angiogenesis associated with relapse and worse outcome.

AB - Objective: To evaluate the association of CXC chemokine ligand 4 (CXCL4) plasma levels with tumour angiogenesis in non-small cell lung cancer (NSCLC) and to assess association of CXCL4 with clinical outcomes. Patients and methods: Fifty patients with early stage NSCLC who underwent pulmonary resection. CXCL4 levels were analysed by ELISA. Angiogenesis was assessed by immunohistochemistry, and microvessel density (MVD) count. Results: There was positive correlation between MVD and CXCL4 levels. Patients with higher CXCL4 levels had worse overall and disease-free survival. Conclusions: Plasma levels of CXCL4 are associated with tumour vascularity. Increased CXCL4 levels in NSCLC patients undergoing treatment may indicate active cancer-induced angiogenesis associated with relapse and worse outcome.

KW - Angiogenesis

KW - chemokines

KW - CXC chemokine ligand 4

KW - non-small cell lung cancer

KW - platelet factor 4

UR - https://www.scopus.com/pages/publications/84964499217

U2 - 10.3109/1354750X.2016.1172111

DO - 10.3109/1354750X.2016.1172111

M3 - Article

C2 - 27098116

AN - SCOPUS:84964499217

SN - 1354-750X

VL - 21

SP - 474

EP - 478

JO - Biomarkers

JF - Biomarkers

IS - 5

ER -

CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment

Abstract

UN SDGs

Keywords*

Field of Science*

Publication Type*

Access to Document

Other files and links

Fingerprint

Cite this